**Global pipeline of products for neglected diseases**

- **576 products under development**
  - **215 Vaccines**
  - **206 Drugs**
  - **138 Diagnostics**
  - **17 Vector Control Products**
  - **153 Tuberculosis**
  - **141 Malaria**
  - **107 HIV/AIDS**
  - **175 Other**

---

**Ongoing need**

**Lack of essential health technologies**

- No HIV/AIDS vaccine
- TB treatment lasts 6–30 months, TB vaccine almost 100 years old
- No suitable treatments for Chagas, leishmaniasis, or mycetoma
- New disease threats continue to emerge

- **214 million** women have unmet need for modern family planning
- **1 billion** people affected by neglected diseases globally
- **6 million** annual deaths worldwide from neglected diseases
Funding for neglected disease R&D

GLOBAL SPENDING ON ALL HEALTH R&D
$281 billion

GLOBAL SPENDING ON NEGLECTED DISEASE R&D
$4 billion

ONLY 1-2% OF GLOBAL SPENDING ON HEALTH R&D TARGETS NEGLECTED DISEASES

GLOBAL SPENDING ON ALL HEALTH R&D
$281 billion

The return on investment of global health R&D

Lives saved
New health innovations resulted in 4.2 million fewer child deaths in 2013, compared to 1990
Antiretroviral therapies prevented 7.8 million deaths from AIDS globally since 2000
The world is on the verge of eradicating polio due to the development and delivery of polio vaccines

Economic growth
$0.89 of every dollar the US government invests in global health R&D goes to US-based researchers and $0.80 of every euro of EU investment is spent within the EU
11% of economic growth in low- and middle-income countries between 2000 and 2011 is attributable to health improvements
US government investment in global health R&D from 2007–2015 generated an estimated 200,000 new US jobs and $33 billion in economic growth

Cost savings
$26 million invested in polio vaccine R&D resulted in treatment cost savings of $180 billion since 1950s
Every $1 invested in HIV/AIDS vaccine R&D is expected to return between $2–67 in cost savings
It cost $50 million to develop a low-cost meningitis A vaccine, which is predicted to have saved $9 billion in treatment costs by 2020

Health security
Without a vaccine or other tools to mitigate the 2014 Ebola outbreak, it claimed 11,000+ lives and cost the US $3 billion and EU €1.2 billion to respond
Pandemics could cost the world $60 billion a year, while investing in the R&D needed to protect against outbreaks would cost only $1 billion a year
By 2050, antimicrobial resistance could lead to 10 million deaths annually and cost the global economy $100 trillion
51% of new global health products approved since 2000 were supported by the US government.

40% of late-stage products in the global health pipeline were supported by the US government.

<.01% of US GDP is spent annually on global health R&D.

While the US leads the world in funding for neglected disease R&D, these investments still account for less than .01% of US GDP.
Infographic Data Sources

Global pipeline for neglected diseases


Funding for neglected disease R&D

R&D $281 billion global spending on all health R&D: Røttingen, J-E, Regmi, S, Eide, M et al. Mapping of available health research and development data: what’s there, what’s missing and what role is there for a global observatory. Lancet. 2013; 383:1286–1307. [Data is for total global spending on health R&D in 2009 purchasing power parity-adjusted dollars, inflation adjusted to 2018 dollars.]


Return on investment in global health R&D


Ongoing need


Critical US role in global health R&D


Top public funders of neglected disease R&D